Hepatic irradiation in the management of metastatic hormone-secreting tumors.
Three patients with extensive liver metastases from hormone-secreting tumors were treated with external beam radiation therapy to palliate signs and symptoms of tumor mass and/or hormone secretion. These patients experienced an objective response of 3, 14, and 24 months duration, respectively, as measured by plasma hormone levels and/or computed tomography (CT) scanning. Using conventional fractionation, a dose of 2400 to 3000 rad was delivered without significant acute or late toxicity. Although these tumors have a long natural history (many years), even after the development of liver metastases, radiation therapy can provide effective palliation and should be considered as a therapeutic option.
Z A
ZA
Tochner
T J
TJ
Kinsella
E
E
Glatstein
D007516:Adenoma, Islet Cell / Q000473:pathology; D000328:Adult; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006393:Hemangiopericytoma / Q000473:pathology; D006801:Humans; D007813:Laparotomy; D008113:Liver Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary*; D008787:Metoclopramide / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000473:pathology; D010307:Parotid Neoplasms / Q000473:pathology; D011836:Radiation Tolerance
D008787:Metoclopramide